Compare Cenovus Energy Inc (CVE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs TransMedics Group Inc — how do they compare? Cenovus Energy Inc trades at $30.2 (market cap $55.00B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Cenovus Energy Inc is far larger — about 17.7× TransMedics Group Inc's market cap, and Cenovus Energy Inc pays a 2.09% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CVE | TMDX | |
|---|---|---|
Market Cap | $55.00B | $3.10B |
Sector | Energy | Technology |
52-Week High | $31.80 | $150.42 |
52-Week Low | $14.83 | $61.99 |
Enterprise Value | $61.08B | $3.49B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.14, up 1.96% with bullish technical signals and strong fundamentals. The stock shows robust earnings momentum with recent quarterly beats, supported by record oil sands production and disciplined cost management. Valuation metrics remain attractive with P/E of 11.56 and EV/EBITDA of 5.77, while profitability metrics include 11.48% net income margin and 20.96% ROE. Recent news highlights institutional buying interest and strong Q2 2026 operational performance.
CVE presents a compelling investment case with undervalued metrics and positive earnings trajectory, though exposure to volatile oil prices and refining margins poses risks. Analyst consensus leans bullish with 40.7% buy ratings, while technical indicators suggest continued upward momentum. The company's integrated model and growth projects support long-term value creation for shareholders.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
